Compugen (CGEN) Q1 2026 earnings review
A Return to Normal Burn Rate, Backed by a Fortress Balance Sheet
After a massive $67.3M milestone-driven revenue spike in 25Q4, Compugen's 26Q1 results represent a return to its baseline clinical-stage burn rate. Revenue normalized to $2.2M (amortized upfront payments), and the company posted a net loss of $7.7M. The real story remains the balance sheet: with $134.9M in cash, Compugen has a runway into 2029. This financial cushion effectively removes near-term dilution risk and bridges the company well past its critical Q1 2027 COM701 MAIA-ovarian trial interim analysis. However, rising R&D costs and a lack of major internal catalysts in 2026 mean investors must rely heavily on partner AstraZeneca to drive the narrative this year.
🐂 Bull Case
The $134.9M cash balance secures operations into 2029. Compugen is fully funded to execute its MAIA-ovarian trial without the constant financing overhang that plagues typical clinical-stage biotechs.
AstraZeneca's expansion of rilvegostomig to 11 Phase 3 trials proves deep commitment. Compugen retains upside through $195M in remaining milestones and tiered royalties on a drug with multi-billion-dollar peak potential.
🐻 Bear Case
The interim analysis for the wholly-owned COM701 asset is pushed to Q1 2027. In the meantime, Compugen is entirely dependent on partner-controlled data releases to drive market interest.
Despite management's conviction in their Fc-reduced design, broader failures in the TIGIT space continue to weigh on market sentiment. Compugen needs undeniable Phase 3 success from AstraZeneca to permanently break this stigma.
⚖️ Verdict: ⚪
Neutral. The financial de-risking is exceptional for a biotech of this size, but the lack of near-term, internally controlled clinical readouts limits immediate upside potential. Execution on the MAIA-ovarian trial remains the core operational focus.
Key Themes
AstraZeneca Partnership Deepens
AstraZeneca's commitment to rilvegostomig (derived from Compugen's COM902) continues to expand, now spanning 11 ongoing Phase 3 trials. AstraZeneca presented clinical and preclinical data at AACR 2026, including late-breaking Phase 2 data in HER2-positive gastric cancer, with more data expected at ASCO 2026. This broad trial strategy maximizes 'shots on goal' for Compugen's future milestone and royalty revenue.
COM701 MAIA-Ovarian Trial Execution
Management confirmed that the MAIA-ovarian trial (COM701 as a single-agent maintenance therapy in relapsed platinum-sensitive ovarian cancer) is actively enrolling across all clinical sites in the U.S., Israel, and France. The trial is a critical test for the anti-PVRIG mechanism, aiming to address a population with significant unmet medical need and no current standard of care.
Unigen AI/ML Platform Validation
Compugen continues to leverage its Unigen AI/ML-powered predictive computational discovery platform to identify novel immune-oncology targets. The clinical progress of assets discovered via Unigen (COM701, rilvegostomig, GS-0321) serves as ongoing validation for the platform's ability to identify mechanisms that established therapies like KEYTRUDA have missed.
Gilead GS-0321 Phase 1 Progression
The Phase 1 trial for GS-0321 (formerly COM503), a potential first-in-class high-affinity antibody blocking the IL-18 binding protein, is progressing as planned. Licensed to Gilead, this asset represents a separate biological pathway and offers up to $758 million in potential future milestones.
R&D Expense Acceleration
Despite a narrative of disciplined execution following the completion of earlier trials, Research & Development expenses accelerated to $6.9M in 26Q1, up 20% from $5.8M a year ago. Management cited rising clinical expenses related to the MAIA-ovarian trial and drug supply costs. If enrollment ramps aggressively, investors should expect cash burn to climb sequentially throughout 2026.
Dependence on Partner-Controlled Data Releases
With the COM701 interim analysis delayed until Q1 2027, 2026 is largely an internal catalyst desert for Compugen. The company is highly reliant on AstraZeneca and Gilead to release data at medical conferences to sustain market momentum. Compugen lacks control over the timing, framing, and strategic disclosure of these key value drivers.
Macro IO Headwinds: The TIGIT Stigma
The broader immuno-oncology sector remains skeptical of the TIGIT pathway following high-profile failures of Fc-active antibodies (e.g., Roche's SKYSCRAPER trials). While Compugen strongly defends its Fc-reduced design, the company is fighting severe industry bias. Until AstraZeneca produces definitive, positive Phase 3 data, the market is likely to discount the probability of success for rilvegostomig.
Other KPIs
Cash decreased by roughly $10.7M from the end of 2025 ($145.6M), reflecting standard operational burn for the quarter. The balance includes cash, equivalents, short-term deposits, and marketable securities, providing a highly comfortable liquidity cushion.
Accelerating slightly. Total OpEx rose from $8.3M in 25Q1 to $9.4M in 26Q1. The increase was entirely driven by clinical trial execution (R&D), while G&A and Marketing expenses remained stable, indicating focused capital allocation toward pipeline advancement.
Guidance
Stable. Management reiterated that current cash balances will fund operating plans into 2029 without factoring in any additional cash inflows from partner milestones. This completely isolates the company from the current volatile biotech funding environment.
Stable vs the most recent update. The timeline for the critical interim analysis of the median progression-free survival (PFS) remains on track for Q1 2027. This confirms that all clinical sites in the U.S., Israel, and France are actively enrolling at expected rates.
Key Questions
Enrollment Velocity for MAIA
With all 28 sites open in the U.S., Israel, and France, what is the current patient enrollment rate for the MAIA-ovarian trial, and are you seeing any elevated competition for patients in the platinum-sensitive setting?
Gilead GS-0321 Data Timeline
While you are executing the Phase 1 trial for GS-0321, Gilead controls data disclosure. Is there any alignment on whether early safety or dose-escalation data might be presented at a medical conference in 2026?
COM902 Monetization Strategy
Given your firm belief in the Fc-reduced TIGIT design, and the fact that you fully own COM902 outside of the bispecific license to AstraZeneca, what specific external triggers (such as Arcus/Gilead data) are you waiting for before actively seeking a partnership for this asset?